By Tony Fong

NEW YORK (GenomeWeb News) – Taking aim at an opportunity that has been estimated at more than $1 billion in the US alone, several firms are using next-generation sequencing and other genomic technologies to break into the diagnostics market for fetal aneuploidy and chromosomal aberrations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.